Catechol-O-methyltransferase genotype as modifier of superior responses to
venlafaxine treatment in major depressive disorder.
Author(s): Hopkins SC(1), Reasner DS, Koblan KS.
Affiliation(s): Author information:
(1)Sunovion Pharmaceuticals Inc, 84 Waterford Dr., Marlborough, MA 01752, USA.
seth.hopkins@sunovion.com
Publication date & source: 2013, Psychiatry Res. , 208(3):285-7
Responses to venlafaxine treatment in major depressive disorder were stratified
by COMT genotypes (Val158Met, rs4680) in a randomized, double-blind,
placebo-controlled clinical trial. Improvements in depression scores among
subjects with Val/Val genotypes were larger than those in Met/Met genotypes,
suggesting that venlafaxine may alter noradrenergic flux differentially according
to COMT activity.
|